Ibrutix 140 mg Ibrutinib

Ibrutinib is a drug that is employed in treating specific forms of blood cancers such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). This drug is a targeted therapy medication, implying that it focuses on particular proteins or molecules that play a role in promoting the growth and survival of cancer cells.

Ibrutinib Indication:

Ibrutinib is indicated for the treatment of the following:

• Chronic lymphocytic leukemia (CLL) in adults, including patients with 17p deletion
• Mantle cell lymphoma (MCL) in adults who have received at least one prior therapy
• Waldenström macroglobulinemia (WM) in adults who have received at least one prior therapy
• Marginal zone lymphoma (MZL) in adults who have received at least one prior anti-CD20-based therapy
• Chronic graft versus host disease (cGVHD) in adults after failure of one or more lines of systemic therapy

Ibrutinib is a targeted therapy drug that targets specific proteins involved in cancer cell growth and survival. It works by blocking Bruton’s tyrosine kinase (BTK), a protein that regulates B-cell growth and survival. B-cell, a type of white blood cell, can become uncontrolled in certain cancers like CLL and MCL. Ibrutinib prevents B cancer cells from receiving necessary signals, leading to cell death or dormancy. It is effective in treating CLL and other blood cancers, improving progression-free and overall survival. It is also convenient and easy to take orally once a day.

Dosage and Absorption:

Ibrutinib is a prescription medication used to treat certain types of blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). It is a targeted therapy drug, which means that it targets specific proteins or other molecules that are involved in the growth and survival of cancer cells.

Dosage

The recommended dosage of ibrutinib is 420 mg taken orally once daily. Ibrutinib can be taken with or without food. It is important to take ibrutinib at the same time each day.

Absorption

Ibrutinib is rapidly absorbed from the gastrointestinal tract with a mean peak plasma concentration (Cmax) reached within 2 hours of oral administration. The absolute bioavailability of ibrutinib is 93%.

Metabolism and excretion

Ibrutinib is a highly protein-bound drug, with approximately 95% of ibrutinib in plasma bound to human albumin. Ibrutinib is metabolized by the cytochrome P450 (CYP) 3A4 enzyme. The major metabolites of ibrutinib are inactive and are excreted in the feces.

The mean elimination half-life of ibrutinib is 4-6 hours. Ibrutinib is primarily excreted in the feces (approximately 80%) and to a lesser extent in the urine (approximately 7%).

Drug interactions

Ibrutinib is a substrate of the CYP3A4 enzyme. Therefore, co-administration of ibrutinib with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, voriconazole) can increase the exposure to ibrutinib, which may increase the risk of side effects.

Ibrutinib is also an inhibitor of the CYP3A4 enzyme. Therefore, co-administration of ibrutinib with drugs that are metabolized by CYP3A4 can increase the exposure to these drugs, which may increase the risk of side effects.

Ibrutinib mechanism of action:

Ibrutinib is a drug that inhibits Bruton’s tyrosine kinase (BTK), a protein that plays a crucial role in the B-cell receptor (BCR) signaling pathway. It works by blocking BTK’s activity, preventing the BCR signaling pathway from being activated, and leading to the death of B cancer cells or dormancy. Ibrutinib is effective in treating chronic lymphocytic leukemia (CLL) and other blood cancers, improving progression-free survival and overall survival. Its mechanism of action involves an antigen binding to the BCR, initiating a signaling cascade that activates BTK, leading to the activation of genes involved in B-cell growth and survival. Ibrutinib is a targeted drug, specifically targeting BTK, minimizing side effects. It has revolutionized the treatment of these diseases and helped many patients live longer and healthier lives.

Ibrutinib Side Effects:

Ibrutinib is commonly used to treat various side effects, including fatigue, diarrhea, nausea, bruising, bleeding, muscle and joint pain, cough, shortness of breath, upper respiratory tract infections, decreased white blood cell and platelet counts, irregular heartbeat, high blood pressure, rash, itching, dry skin, headache, constipation, abdominal pain, weight loss, fever, chills, back pain.

Ibrutix 140mg Ibrutinib Cost:

The cost of ibrutinib (Imbruvica) varies depending on several factors, including the dose, the number of capsules, and the pharmacy where you purchase it. In the United States, the cash price for a 28-day supply of ibrutinib 420 mg capsules is around $16,734. But most of the people can not afford at this price we are giving best price in the market so that every one can avail this medicine. To buy Ibrutinib at best price contact with us.

Ibrutix 140 mg Ibrutinib and CLL:

Ibrutinib is a targeted therapy drug for treating chronic lymphocytic leukemia (CLL) by blocking Bruton’s tyrosine kinase (BTK), a protein involved in cancer cell growth and survival. It improves progression-free survival and overall survival in CLL patients. Ibrutinib is well-tolerated with common side effects like fatigue, diarrhea, and nausea. FDA approved for adults with 17p deletion and prior therapy, it is taken orally once a day. It is a convenient and easy-to-take drug, making it a popular choice for CLL patients.

See Acute myeloid lymphoma treatment medication Ivosenib.